Levinson I, Galynker I I, Rosenthal R N
Beth Israel Medical Center, Department of Psychiatry, New York, NY 10003.
J Clin Psychiatry. 1995 Feb;56(2):73-6.
Methadone is a typical mu-opioid receptor agonist that is widely used for maintenance and detoxification treatment of opiate-dependent patients. Although methadone withdrawal syndrome is well described, it generally does not include psychosis.
Having observed new onset psychosis in a patient on methadone taper, the authors identified three other such patients by chart review. All met DSM-III-R criteria for opioid dependence. Distinctive features of their clinical presentation, pharmacotherapy received, and follow-up were recorded.
Two patients had no history of psychosis, one patient had a psychotic episode 21 years prior to admission, and one patient was diagnosed with schizophrenia but remained asymptomatic for at least 1 year while treated with only methadone. Psychosis resolved spontaneously in one case, whereas the other cases required neuroleptic treatment. In one case, methadone resumption was required. None of the patients developed typical methadone withdrawal syndrome.
The above results suggest that opioid taper may be a period of high risk for development of psychosis. This risk is probably higher in patients with preexisting CNS illness. Clinicians caring for patients in opioid withdrawal should be aware of this risk. Further research is required to evaluate whether methadone withdrawal psychosis represents a clinical manifestation of opioid agonist modulation of dopaminergic neurotransmission in the human brain.
美沙酮是一种典型的μ-阿片受体激动剂,广泛用于阿片类药物依赖患者的维持和脱毒治疗。虽然美沙酮戒断综合征已有详细描述,但通常不包括精神病。
在观察到一名正在逐渐减少美沙酮用量的患者出现新发精神病后,作者通过查阅病历又确定了另外三名此类患者。所有患者均符合DSM-III-R阿片类药物依赖标准。记录他们临床表现的显著特征、接受的药物治疗及随访情况。
两名患者无精神病病史,一名患者在入院前21年有过一次精神病发作,一名患者被诊断为精神分裂症,但仅用美沙酮治疗时至少1年无症状。一例精神病自行缓解,而其他病例需要使用抗精神病药物治疗。有一例需要恢复使用美沙酮。所有患者均未出现典型的美沙酮戒断综合征。
上述结果表明,减少阿片类药物用量可能是发生精神病的高风险期。在已有中枢神经系统疾病的患者中,这种风险可能更高。照顾阿片类药物戒断患者的临床医生应意识到这种风险。需要进一步研究以评估美沙酮戒断性精神病是否代表人脑中阿片类激动剂对多巴胺能神经传递调节的一种临床表现。